Journal
SEMINARS IN LIVER DISEASE
Volume 40, Issue 3, Pages 240-255Publisher
THIEME MEDICAL PUBL INC
DOI: 10.1055/s-0040-1708806
Keywords
cirrhosis; hepatic venous pressure gradient; elastography; von Willebrand factor
Categories
Funding
- European Association for the Study of the Liver
- Andrew K. Burroughs Short-TermTraining Fellowship of the European Association for the Study of the Liver
Ask authors/readers for more resources
Noninvasive diagnostics for portal hypertension include imaging and functional tests, as well as blood-based biomarkers, and capture different features of the portal hypertensive syndrome. Definitive conclusions regarding their clinical utility require assessment of their diagnostic value in specific clinical settings (i.e., diagnosing a particular hemodynamic condition within a well-defined target population). Several noninvasive methods are predictive of clinically significant portal hypertension (CSPH; hepatic venous pressure gradient [HVPG]>= 10mmHg; the threshold for complications of portal hypertension); however, only a minority of them have been evaluated in compensated advanced chronic liver disease (i.e., the target population). Importantly, most methods correlate only weakly with HVPG at high values (i.e., in patients with CSPH). Nevertheless, selected methods show promise for diagnosing HVPG >= 16mmHg (the cut-off for increased risks of hepatic decompensation and mortality) and monitoring HVPG changes in response to nonselective beta-blockers or etiological treatments. Finally, we review established and potential future clinical applications of noninvasive methods.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available